Back to Search Start Over

Ethris receives UK MHRA nod to begin phase I study of ETH47, a first-in-class inhaled mRNA for respiratory viral infections

Source :
PharmaBiz. November 29, 2023
Publication Year :
2023

Abstract

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced that it has received approval from the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.774672012